Joji Tani
Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 281 publications
Teachable Moments in Alcohol-Related Diseases: A Practical Framework for Promoting Abstinence in General Internal Medicine.
Journal: Internal medicine (Tokyo, Japan)
Published: September 02, 2026
Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.
Journal: Clinical nutrition ESPEN
Published: June 13, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 29, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Journal: Oncology
Published: April 19, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 07, 2026
Constipation in Older Adults: Pathophysiology, Clinical Impact, and Management Strategies.
Journal: Geriatrics (Basel, Switzerland)
Published: February 22, 2026
Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.
Journal: Alimentary pharmacology & therapeutics
Published: February 05, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: January 27, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
Journal: Journal of gastroenterology and hepatology
Published: January 19, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 13, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 12, 2026
Last Updated: 09/26/2026